Further re. Annual General Meeting

RNS Number : 3576D

HeiQ PLC

28 June 2021

 

28 June 2021

HeiQ Plc

("HeiQ" or "the Company")

Further re. Annual General Meeting

Further to the Company's recent announcement regarding the passing of resolutions at its Annual General Meeting ("AGM"), a copy of resolutions 12 to 14, being the special resolutions passed at the AGM, have been submitted to the National Storage Mechanism as required by Listing Rule 9.6.2R, and will shortly be available for inspection at  https://data.fca.org.uk/#/nsm/nationalstoragemechanism . 

For further information, please contact:

HeiQ Plc Carlo Centonze (CEO)	[phone]
Arlington Group Asset Management Limited (Financial Advisor and Joint Broker) Charles Cannon Brookes	[phone]
Cenkos Securities plc (Joint Broker) Stephen Keys / Callum Davidson	[phone]
SEC Newgate (Media Enquiries) Elisabeth Cowell / Megan Kovach	[phone] HeiQ@s ecnewgate .co.uk

About HeiQ

HeiQ is focused on improving the lives of billions of people world-wide by innovating the materials people use every day. It is an IP-rich pioneer which is at the forefront of global technology in the $10 billion antimicrobial fabrics and $24 billion textile chemicals market. It has also moved into the medical device, healthcare and probiotics markets, to help make hospitals and healthcare environments more hygienic.

HeiQ has created some of the most effective, durable and high-performance technologies and textile effects in the market today, which cool, warm, dry, repel, purify, and destroy viruses. Since 2005, HeiQ has developed over 200 technologies in partnership with 300 major brands. It has won multiple awards and gained a strong reputation for sustainability.

Led by an experienced management team, HeiQ rapidly researches new solutions for partners, quickly delivers scaled up manufacturing from its sites across the world and helps partners market the product to end consumers - aiming for lab to consumer in months.

HeiQ aims to deliver growth for its shareholders through a combination of increased sales of its core products and by entering additional lucrative markets through disruptive innovations and M&A. It has a healthy R&D pipeline containing over 40 projects.  

 

END

 

 

FURDKFBQBBKDDAB